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A hallmark of malignancy is excessive tumor glycolysis, even in the presence of oxygen, which causes lactacidosis in the tumor microen-
vironment and favors tumor cell proliferation and survival. For this reason antimetabolic agents which target tumor cell metabolism are 
being researched extensively as promising anticancer drugs. Aim: To study the effect of lactacidosis on survival of Lewis lung carcinoma 
(LLC) cells at the conditions of nutritional substrate deficiency in vitro and evaluate antitumor and antimetastatic activity against LLC/
R9 in vivo. Materials and Methods: LLC variant LLC/R9 was used as experimental tumor model. Tumor cell viability was determined 
using trypan blue staining. Apoptosis level was counted with the use of Hoechst 33258 dye. Lactate content in the tumor tissue was 
evaluated by enzyme method with the use of lactate dehydrogenase. Reactive oxygen species was determined using 2.7-dichlorofluorescein 
diacetate. Effects of dichloroacetate (DCA) on the growth and metastasis of LLC/R9 were analyzed by routine procedures. Evaluation 
of DCA effect toward electron-transport chain (ETC) components was performed using EPR. Results: It has been shown that at the 
conditions of lactacidosis and glucose deficiency, LLC/R9 cell viability in vitro was higher by 30% (р < 0.05) and apoptosis level was 
triply lower (р < 0.05) than these indices at the conditions of glucose deficiency only. In mice with transplanted LLC/R9 tumors treated 
for 3 weeks per os with DCA at the total dose of 1.5 g/kg of body weight starting from the next day after tumor transplantation, the pri-
mary tumor volume was just by 30% lower than that in control group. At the same time, the number and volume of lung metastases 
in animals treated with DCA were by 59% (р < 0.05) and 94% (р < 0.05) lower, respectively, than these indices in the control group. DCA 
treatment resulted in nearly 30% increase (р < 0.05) of lactate content in tumor tissue compared to that in the control, but did not affect 
significantly the levels of heme iron complexes with NO (at gmed = 2.007) in mitochondrial ETC proteins and Fe-S cluster proteins (at g 
= 1.94) in tumor cells. Conclusions: It has been shown that lactacidosis significantly promoted LLC/R9 cell survival at the conditions 
of glucose deficiency in vitro. If LLC/R9 developed in vivo, DCA as the compound with antilactacidosis activity did not suppress signifi-
cantly the primary tumor growth but exerted significant antimetastatic activity.
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It is well known that lactacidosis, large accumulation 
of lactate and decrease of рН, is the main characteris-
tics of metabolic tumor cell microenvironment in vitro 
and in vivo. Earlier lactacidosis has been considered 
as a ballast product of tumor cell metabolism. However, 
recently it has been shown that it could be used by tu-
mor cells as an effective energetic fuel and be among 
the factors responsible for tumor resistance to glucose 
deficiency [1–3]. As we have shown using Lewis lung 
carcinoma (LLC)/R9 cells, LLC variant sensitive to an-
tiangiogenic cancer therapy [4, 5], lactacidosis could 
promote tumor cell survival at the conditions of nutri-
tional deficiency. Such conditions were generated via 
long-term incubation of tumor cells without replace-
ment of culture medium (“unfed culture” model) [6]. 
The study of tumor cell growth kinetics at the conditions 
of “unfed culture” has demonstrated that at the back-
ground of complete absence of glucose in incubation 
medium at days 7–8 of cell growth the viable cell counts 
did not fall below the third part from their maximum 
registered at days 3–4, and remained practically at this 
level till the 10th day. High survival rate of LLC/R9 cells 
at the conditions of “unfed culture” was related in par-
ticular to the ability of these cells to macroautophagy. 
However, it could not be excluded that the ability of LLC/
R9 cells for adaptation toward nutritional substrate defi-
ciency was determined by lactacidosis which developed 
as a consequence of prolonged tumor cell culturing 
without replacement of incubation medium.
If lactacidosis is capable to increase tumor cell 
survival, then the compounds suppressing lactacidosis 
formation in tumor microenvironment, in particular, di-
chloroacetate (DCA) as a compound with antilactacidosis 
activity should demonstrate antitumor activity. The pre-
sent study was aimed on the testing of such assumption.
It is known that DCA is an inhibitor of pyruvate de-
hydrogenase kinase (PDK), that’s why it is considered 
as a negative regulator of enzymes of mitochondrial py-
ruvate dehydrogenase (PDH) complex which plays a key 
role in the regulation of tricarboxylic acid and oxidative 
phosphorylation [7]. If PDH complex is phosphorylated, 
an entry of pyruvate in Krebs cycle is inhibited, so gly-
colysis is being activated. Due to PDK inhibition, DCA 
is capable to lead for indirect activation of PDH com-
plex enzymes and respectively causes the shift of cell 
energetic balance from glycolysis toward activation 
of oxidative phosphorylation. Therefore, DCA has been 
widely used for correction of lacticemia caused by high 
intensity of glycolysis or defective cell respiration.
According to the data of literature, an ability of DCA 
to activate oxidative phosphorylation underlies its 
antitumor activity and is realized, in particular, via 
the decrease of lactacidosis and induction of reactive 
oxygen species (ROS) [8–12]. The aim of our study 
was to analyze an influence of lactacidosis on survival 
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of LLC/R9 cells at the conditions of nutrient deficiency 
in vitro and evaluate antitumor and antimetastatic acti-
vity of DCA against LLC/R9 in vivo.
MATERIALS AND METHODS
Experimental animals, tumor cells. The study 
was carried out using 2.0–2.5 months old C57Bl/6 mice 
weighting 18–23 g, bred at animal facility of R.E. Ka-
vetsky Institute of Experimental Pathology, Oncology 
and Radiobiology of the NAS of Ukraine. Animal study 
protocols and operation procedures were carried out 
in accordance with the main requirements to keeping 
and working with laboratory animals and to the rules 
of local Bioethics Committee.
In the study LLC variant LLC/R9 derived from wild-
type LLC strain by 9 sequential chemotherapy in vivo 
sessions based on cis-diamminedichloroplatinum (cis-
DDP), was used [13]. LLC/R9 cells were maintained 
in RPMI culture medium (Sigma, USA) supplemented 
with 10% fetal calf serum (FCS) (Sigma, USA), and 
40 g/ml gentamycine at 37 °C in humidified atmo-
sphere with 5% CO2.
Experiments in vitro. Cell counts in suspension 
and their viability was routinely analyzed on a hemo-
cytometer using trypan blue exclusion test.
For evaluation of effects of lactacidosis on viabi lity 
of LLC/R9 cells, 1.5•105 cells/well were seeded in 24-
well plate in RPMI 1640 medium (Sigma, USA) with 
standard glucose content. After overnight incubation 
cell incubation medium was replaced with the fresh 
media with different content of glucose, lactate and 
with different pH for simulation of the conditions 
of glucose deficiency, lactacidosis at the background 
of glucose deficiency, as well as standard (Table 1). 
Glucose deficient medium was prepared on the basis 
of RPMI 1640 medium without glucose (Sigma, USA). 
Lactacidosis was generated by adding pure lactic acid 
(Sigma, USA) to glucose deficient medium to a final 
concentration of 14 ± 0.7 mM and pH 6.7.
Table 1. The content of glucose, lactate and pH of culture media used 
in the study
Medium Glucose content, mM
Lactate content, 
mM рН
Standard 9.0 ± 0.5 1.6 ± 0.1 7.4 ± 0.01
Glucose deficiency 3.0 ± 0.1 1.6 ± 0.1 7.4 ± 0.01
Lactacidosis 3.0 ± 0.1 14.0 ± 0.7 6.7 ± 0.01
Effect of different incubation conditions upon tu-
mor cell survival, ROS production, glucose consump-
tion and lactate production were estimated on the 2nd 
day of tumor cell incubation.
Glucose content in culture media and in tumor 
tissue homogenates was determined by enzyme 
glucose-oxidant method using the kit for glucose 
analysis in biologic fluids (Sigma, USA) according 
to instructions of the manufacturer. Lactate content 
in incubation media and in tumor tissue homogenates 
was determined by enzyme spectrophotometry me-
thod using lactate dehydrogenase (Sigma, USA) [14]. 
Medium and tumor tissues samples were collected and 
stored at −20 °С or in liquid nitrogen, correspondently, 
until the measurement performance.
Apoptosis level in tumor cells was analyzed with 
the use of Hoechst 33258 dye (Sigma, USA) and fluo-
rescent microscopy by standard method.
Production of ROS in tumor cells was determined 
with the use of 2.7-dichlorofluorescein diacetate (Sig-
ma, USA) by spectrofluorometry (excitation at 495 nm, 
emission at 530 nm) according to [15].
All measurements were repeated.
Experiments in vivo. For in vivo experiments, 
LLC/R9 cells were propagated in vitro at standard con-
ditions and were inoculated i.m. to mice (1.0•106 cell/
animal in 0.1 ml of Hanks’ solution).
After LLC/R9 cell inoculation the animals were dis-
tributed into 2 groups: group 1 — mice treated with DCA 
(Sigma, USA) at the total dose of 1.5 g/kg (LD50/3) 
(n = 13); group 2 — mice treated with water at the same 
regimen and in the same volume (control, n = 12).
The treatment has been initiated on the following 
day after tumor cell transplantation at metronomic 
regimen, 5 times per week for 3 weeks. DCA was 
prepared ex tempore in water, and was administered 
per os in a volume of 0.4 ml/animal.
Primary tumor volume was calculated on the basis 
of its diameter measured using caliper each 3rd day 
starting from the 10th day after tumor cell inoculation, 
by the formula:
V = π (d)3/6,
where d — diameter of tumor (mm).
Metastasis level in tumor bearing mice was 
evaluated at the 21st day after tumor cell inoculation 
by the number and volume of lung metastases using 
binocular microscope and millimeter scale.
Total volume of metastasis was calculated 
by the formula:
V = Σ ni π(di)3/6,
where V — total volume of metastases (mm3), ni — 
number of metastases with the diameter of di (mm).
Analysis of functional activity of mitochondrial 
respiratory chain components in tumor cells was per-
formed with the use of EPR at the 21st day after tumor 
cell inoculation. Tumor tissue was cut into the samples 
of special size (d = 4.0 mm, l = 25–35 mm), frozen and 
stored at −70 °C. EPR analysis of the samples was per-
formed at 77 К using spectrophotometer Е-109 Var-
ian (USA) at potential sweep speed of 500 Е/min, 
modulation amplitude of 1.25×10 Е, power of SHF-
irradiation of 10.0 mW, constant session of apparatus 
of 1.0 s. The levels of heme iron complexes with NO 
(at gmed = 2.007) in mitochondrial ETC proteins and 
Fe-S cluster proteins (at g = 1.94) in tumor cells were 
determined by the data of EPR spectra.
Statistical analysis of obtained results was car-
ried out by descriptive methods, nonlinear regression 
analysis and Student’s t-test with the use of Microsoft 
Excel and Microcal Origin programs.
RESULTS
It has been shown that lactacidosis at the condi-
tions of glucose deficiency significantly promoted 
survival of LLC/R9 cells. Indeed, growth kinetics of tu-
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mor cells incubated at the conditions of lactacidosis 
at the background of glucose deficiency did not differ 
significantly of that of the cells incubated in the me-
dium with standard glucose content, at least at the pe-
riod of their exponential growth. In particular, viable cell 
counts at the 2nd day of incubation at the conditions 
of lactacidosis at the background of glucose deficiency 
was practically the same as in the case of cell incuba-
tion in the medium with standard glucose content. 
At the same time, in both cases (lactacidosis and 
standard) the viable cell counts were nearly by higher 
30% (р < 0.05) than in the case of cell incubation 
at the conditions of glucose deficiency itself (Fig. 1, a).
Apart from this, the number of apoptotic cells 
at the conditions of lactacidosis also did not differ 
statistically from that index in the case of cell incuba-
tion in the medium with standard glucose content and 
at the 2nd day was equal to 8.5 ± 0.9%, while at the con-
ditions of glucose deficiency the number of apoptotic 
cells was nearly three times higher (p < 0.05) than that 
in the case of lactacidosis (Fig. 1, b).
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Fig. 1. LLC/R9 cell survival on the 2nd day of their incuba-
tion in standard (1), glucose deficient (2) and lactacidosis (3) 
media; a — the number of viable cells; b — apoptosis level. 
*p < 0.05 compared to control
Interestingly, at the conditions of lactacidosis 
in LLC/R9 cells glucose consumption was significantly 
lower. Low rate of glucose consumption by tumor cells 
upon lactacidosis registered just at 1st day of their in-
cubation, has been restored at 2nd day and was by 70% 
lower (p < 0.05) than that in the case of the medium with 
standard glucose content (Table 2). In the case of glu-
cose deficiency in contrary to lactacidosis at 2nd day the 
level of glucose in incubation medium fall to zero, what 
additionally evidenced on decreased glucose consump-
tion by LLC/R9 cells at the conditions of lactacidosis.
While lactacidosis led to decreased rate of glucose 
intake by LLC/R9 cells, the level of intracellular ROS 
in the cells that survived at such conditions significantly 
increased. These data are presented in Table 2 and 
demonstrate that ROS level in the cells incubated 
at the conditions of lactacidosis was nearly by 150% 
(p < 0.05) and 230% (p < 0.05) higher than corre-
sponding indices for the cells incubated in standard 
and glucose-deficient media, respectively.
So, the obtained data have demonstrated that 
lactacidosis significantly promoted LLC/R9 cell sur-
vival at the conditions of glucose deficiency in vitro 
what is supported by high counts of the cells survived 
at such unfavorable conditions, and by low apoptosis 
rate. The cell survival was associated with unexpected 
increase of intracellular ROS level and decreased glu-
cose consumption in LLC/R9.
Table 2. The effect of lactacidosis at the condition of the glucose deficiency 
upon glucose consumption and ROS production by tumor cells in vitro
Medium Glucose consumption, % ROS, %
Standard 100.0 ± 5.9 100.0 ± 24.8
Glucose deficiency 0.0 ± 0.0* 75.8 ± 10.7
Lactacidosis 29.8 ± 1.5* 248.7 ± 53.2*
Note: *p < 0,05.
These patterns of survival of LLC/R9 cells 
at the conditions of lactacidosis at the background 
of glucose deficiency in vitro evidenced on the fact 
that decreased lactate content in tumor microenviron-
ment may prevent tumor cell survival at the conditions 
of metabolic stress therefore exerting antitumor effect. 
Such hypothesis was tested by us with the use of DCA 
as a compound capable to reduce lactacidosis.
The data on DCA influence on LLC/R9 growth 
kinetics and metastasis are shown on Fig. 2 and 
Table 3. According to these data, DCA did not affect 
significantly the growth of primary tumors, but caused 
an expressed suppression of metastasis. The growth 
kinetics of primary tumors in mice with LLC/R9 treated 
with DCA did not practically differ from that in control 
mice, and at the 21st day after tumor transplantation 
the volume of primary tumors in experimental group 
was just by 39% lower than that in the control group 
(see Fig. 2, Table 3). Despite the fact that DCA exerted 
no notable suppression of primary tumor growth, 
its antimetastatic activity toward LLC/R9 was found 
to be striking. The number and volume of lung me-
tastases in tumor bearing mice treated with DCA were 
by 59% (р < 0.05) and 94% (р < 0.05) lower than these 
indices in control group, respectively (see Table 3).
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Fig. 2. The effect of DCA upon LLC/R9 growth kinetics in vivo
Table 3. Influence of DCA on LLC/R9 growth and metastasis
Group of mice Tumor volume,mm3
Number of me-
tastasis
Volume of metastasis, 
mm3
Control (n = 13) 1702.7 ± 333.9 10.9 ± 1.2 17.9 ± 5.6
DCA (n = 13) 1046.0 ± 258.3 4.5 ± 1.6* 1.1 ± 0.4*
Note: *р < 0.05, differences are significant as compared to the value for control.
An analysis of lactate content in tumor tissue 
samples has demonstrated that unexpectedly DCA 
caused significant increase of lactate content in tumor 
tissue, at least at the 21st day after tumor transplan-
tation. As one may see in Table 4, lactate content 
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in tumor tissue of mice treated with DCA, was nearly 
by 30% higher (р < 0.05) than that in the control. 
Accounting an ability of DCA as PDH kinase inhibitor 
reorganize energetic metabolism of malignant tumor 
toward oxidative phosphorylation, we have consi dered 
the lactate production by tumor cells as a surrogate 
marker of glycolysis inhibition upon DCA influence. 
The increase of lactate level in tumor caused by DCA 
indicated that its administration to mice with LLC/
R9 at a total dose of 1.5 g/kg of animal body weight 
could be insufficient for activation of oxidative phos-
phorylation in tumor cells what explains in part its low 
efficacy against primary tumors.
Table 4. Influence of DCA on the lactate level in tumor tissue of LLC/R9-
bearing mice
Group of mice Lactate (μmol/1 g tissue)
Control (n = 4) 11.1 ± 0.6
DCA (n = 5) 14.4 ± 1.5*
Note: р < 0.05, differences are significant as compared to the value for control.
An analysis of EPR spectra of tumor samples has 
shown that DCA did not affect significantly the functional 
state of the ETC components in tumor cell mitochondria 
(Table 5). For example, in mice with LLC/R9 treated 
with DCA, an intensity of EPR signals corresponding 
to nitrosyl-heme iron protein complexes (gсер = 2.007) 
in ETC proteins of tumor cell mitochondria was not 
significantly higher than that in control mice. It is known 
that accumulation of NO-complexes of hem iron may 
indicate from one side the redox imbalance toward 
domination of free radical processes, in particular, 
NO hyperproduction, and from other side on possible 
inhibition of cell respiration via nitrosylation of heme 
proteins. However, DCA, the main mechanism of an-
titumor action of which is thought to be related to the 
induction of ROS production by mitochondria [8, 10, 
11], did not cause elevation of heme iron complexes 
with NO in tumor tissue. The latest observation could 
be possibly related to the features of LLC/R9 cells, 
namely, an extremely high content of these complexes 
characteristic for this tumor and progressive accumula-
tion of which during tumor development in vivo has been 
registered by us even in the absence of treatment [16].
Table 5. Influence of DCA on the mitochondrial ETC activity of tumor cells
Group of mice
Relative EPR signal intensity
Nitrosyl-heme iron protein 
complexes (g = 2.007)
Fe-S protein 
(g = 1.94)
Control 54.3 ± 4.5 15.8 ± 0.5
DCA 97.8 ± 30.1 17.8 ± 2.1
An absence of significant effect of DCA on func-
tional activity of mitochondrial ETC components in tu-
mor cells was also supported by the data on intensity 
of EPR signals corresponding to Fe-S cluster proteins 
(g = 1.94) (complexes І, ІІ, ІІІ), that was practically 
equal in both animal groups (see Table 5).
In conclusion, the results of our study have shown 
that lactacidosis significantly promoted the survival 
of LLC variant LLC/R9 at the conditions of glucose de-
ficiency. At the same time, if LLC/R9 developed in vivo 
DCA did not exert antitumor activity against primary 
tumors. The failure of antitumor action of DCA against 
LLC/R9 growth was in agreement with the absence 
of DCA inhibition effect on lactate content in the tumor 
as well as an absence of notable DCA effect on tumor 
cell ROS production. Although DCA did not affect 
LLC/R9 growth but drastically inhibited metastasis; 
this observation could not be explained by DCA action 
within primary tumor and further additional studies 
of its antimetastatic action are required.
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